Status:
UNKNOWN
The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications
Lead Sponsor:
Silesian Centre for Heart Diseases
Collaborating Sponsors:
Medical Research Agency, Poland
Medical University of Silesia
Conditions:
COVID-19
Coronavirus Infection
Eligibility:
All Genders
18-120 years
Brief Summary
SAR-Cov-2 infection and its clinical manifestation known as COVID-19 beside the respiratory and lung involvement may include the cardiovascular system, the nervous system and the liver. In the acute p...
Eligibility Criteria
Inclusion
- SARS-Cov-2 RNA confirmed by the PCR method in the acute phase of disease.
- Presence of the clinical symptoms associated with COVID-19 in the acute phase of disease
- Two negative results of SARS-COV-2 PCR test following the 7-day period of quarantine
- Informed consent
Exclusion
- Any symptoms of infection during the quarantine
- Lack of patient's consent
- Lack of possibility of travelling to the hospital for tests
Key Trial Info
Start Date :
June 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04453748
Start Date
June 8 2020
End Date
November 30 2021
Last Update
September 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Silesian Centre for Heart Disease
Zabrze, Silesian Voivodeship, Poland, 41-800